Pyrazolyl-Tetrazoles and Imidazolyl-Pyrazoles as Potential Anticoagulants and their Integrated Multiplex Analysis Virtual Screening
作者:André Lourenço、Percilene Vegi、Jéssica Faria、Gustavo Pinto、Maurício dos Santos、Plínio Sathler、Max Saito、Marcos Santana、Tatiana Dutra、Carlos Rodrigues、Robson Monteiro、Alice Bernardino、Helena Castro
DOI:10.21577/0103-5053.20180150
日期:——
( )This article reports a novel virtual screening algorithm seeking the rational identification of novel lead anticoagulants. Seven 5-(3-methyl-1-aryl-1H-pyrazol-4-yl)-1H-tetrazoles and seven novel 1-aryl-4-(4.5-dihydro-1H-imidazol-2-yl)-3-methyl-1H-pyrazoles were obtained in three steps starting from arylhydrazine hydrochlorides as raw materials in good yields: 50-72% and 50-85%, respectively. All compounds were submitted to an in silico target-base pipeline named integrated multiplex analysis virtual screening (IMA-VS), which comprises the evaluation of their (i) fitting physicochemical properties to the chemical environment of the target enzyme; (ii) active-site homing electrostatic potential to the target enzyme; (iii) structural fitting to the target active site through molecular docking; and (iv) overall absorption, distribution, metabolism, excretion and toxicity (ADMET) profile. After the virtual selection of potential anticoagulant hits, all molecules were synthesized and candidates were evaluated in vitro for their anticoagulant and hemolytic profile. The most promising candidate pointed out by IMA-VS was compound 1-(3',4'-dichlorophenyl)-4-(4,5-dihydro-1H-imidazol-2-yl)-3-methyl -1H-pyrazole that shown to display factor Xa (FXa)-specific inhibitory activity in vitro, acting as an uncompetitive inhibitor with an inhibition constant (Ki) = 61.16 +/- 12.96 mu M, in addition to the lowest hemolytic activity of the series. Further experiments revealed the antithrombotic activity of this compound in an in vivo model of arterial thrombosis induced by FeCl3.
本文报道了一种新颖的虚拟筛选算法,旨在合理识别新型抗凝血药物先导物。从联胺盐酸盐出发,通过三步合成路线分别以50-72%和50-85%的优良收率获得了7种5-(3-甲基-1-芳基-1H-吡咯并[1,2-b]咪唑-4-基)-1H-四氮唑和7种新型1-芳基-4-(4,5-二氢-1H-咪唑-2-基)-3-甲基-1H-吡咯并[1,2-b]咪唑。所有化合物均提交给一个基于靶点的体外虚拟筛选管道(综合多梯度分析虚拟筛选(IMA-VS)),其中包括对(i)其物理化学性质与靶点酶化学环境的契合性;(ii)靶点酶活性位点的静电势;(iii)通过分子对接对靶点活性位点的结构契合性;以及(iv)整体吸收、分布、代谢、排泄和毒性(ADMET)轮廓的评估。IMA-VS在虚拟筛选出潜在抗凝血药物候选物后,所有分子均被合成,并在体外进行了抗凝活性和溶血活性评价。由IMA-VS指向的最有望候选物1-(3',4'-二氯苯基)-4-(4,5-二氢-1H-咪唑-2-基)-3-甲基吡咯并[1,2-b]咪唑表现出体外对因子Xa(FXa)的特异性抑制活性,作用为一种非竞争性抑制剂,其抑制常数(Ki)为61.16 ± 12.96 µM,同时具有系列中最低的溶血活性。进一步的实验揭示了该化合物在由FeCl3诱导的动脉血栓形成的小鼠模型中的抗血栓活性。